Nuveen LLC Takes Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Nuveen LLC bought a new stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 194,897 shares of the company's stock, valued at approximately $1,056,000. Nuveen LLC owned 0.28% of Eyepoint Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in EYPT. GAMMA Investing LLC increased its position in Eyepoint Pharmaceuticals by 3,174.4% during the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after purchasing an additional 9,936 shares during the period. Raymond James Financial Inc. purchased a new position in Eyepoint Pharmaceuticals during the 4th quarter valued at about $76,000. Arizona State Retirement System increased its position in Eyepoint Pharmaceuticals by 12.7% during the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after purchasing an additional 1,877 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Eyepoint Pharmaceuticals during the 4th quarter valued at about $91,000. Finally, New York State Common Retirement Fund increased its position in Eyepoint Pharmaceuticals by 208.8% during the 1st quarter. New York State Common Retirement Fund now owns 20,114 shares of the company's stock valued at $109,000 after purchasing an additional 13,600 shares during the period. Hedge funds and other institutional investors own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Price Performance

EYPT traded down $0.12 during trading on Thursday, reaching $11.88. 742,789 shares of the company's stock were exchanged, compared to its average volume of 789,312. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.98. The stock has a market capitalization of $818.89 million, a P/E ratio of -4.43 and a beta of 1.93. The company's fifty day simple moving average is $10.60 and its 200-day simple moving average is $7.96.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The business had revenue of $5.33 million for the quarter, compared to analysts' expectations of $6.82 million. Equities analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on EYPT shares. Mizuho lowered their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Chardan Capital restated a "buy" rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. HC Wainwright raised their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, Royal Bank Of Canada started coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $26.86.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.